IRVINE, Calif., May 21, 2017 -- Pain Management Center of Irvine recently released information on the superiority of SurForce® compared to prolotherapy or PRP. Unlike the alternatives, which take hours per appointment, SurForce® only requires 15 minutes per session. SurForce® is also painless, while the other two options can be painful. The SurForce® treatments also promote healing rather than only managing pain.
Prolotherapy is an older treatment method that involves injecting dextrose into painful tissues to intentionally cause an inflammatory response. The underlying belief is that it will cause the body to speed healing in the inflamed area as well as the injured part. In practice, however, it is used to manage pain instead of to regenerate tissue. Unfortunately, the inflammation it brings on actually causes pain for the duration of the treatments.
Platelet Rich Plasma (PRP) is a stem cell therapy made up of blood, bone marrow, and fat (adipose) tissue. Getting these ingredients involves sucking bone marrow and fat out of the patient's body, and this is said to be a very painful process. It is even worse for older patients since they have fewer viable stem cells and need to donate more tissue to make up for this.
"It is clear that these older methods each have significant shortcomings. This is why we decided to implement the SurForce® system instead. SurForce® combines amniotic membrane tissue, biological scaffolding, and hyaluronic acid to provide a strong healing boost to painful areas via the addition of stem cells. This not only relieves pain, but allows the body to heal faster. Even better, this treatment is delivered by a painless injection," explained Dr. Rick Letts of Pain Management Center of Irvine.
Many people have questions when they learn that amniotic membrane is part of the SurForce® treatment. Specifically, they want to know where it comes from. There is no need for concern over this aspect of SurForce®. The FDA regulated amniotic membrane is voluntarily donated by women who have had cesarean deliveries.
Like many other healing treatments, SurForce® takes several weeks to fully implant in a patient, which is when the most noticeable improvement to their condition can be observed. Therefore, patients are advised to stick to light activity for the first few weeks. This ensures that everything will heal properly and prevent further injury during the course of treatment.
About Pain Management Center of Irvine
The Center offers a wide variety of pain management treatments, ranging from advanced stem cell therapy all the way to traditional healing methods like acupuncture and cupping. It serves the area of Irvine, CA.
To learn more about SurForce®, visit the Pain Management Center of Irvine’s website at http://chirocenterofirvine.com/.
Pain Management Center of Irvine 4902 Irvine Center Dr. #201 Irvine, CA 92604 (949) 857-4712


Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



